Karyopharm Therapeutics Implements 1-for-15 Reverse Stock Split to Boost Share Value

Karyopharm Therapeutics Announces Reverse Stock Split

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company renowned for its innovative cancer therapies, has made an important announcement regarding its stock. Effective February 25, 2025, the company will execute a 1-for-15 reverse stock split. This strategic move was sanctioned by the stockholders during a special meeting held on January 30, 2025, and aims to enhance the per-share market price of Karyopharm’s stock, thereby ensuring compliance with Nasdaq’s minimum bid price requirement.

Understanding the Reverse Stock Split

In a reverse stock split, the company will merge every 15 existing shares into just one, leading to a reduction in the total number of shares from approximately 126.2 million to roughly 8.4 million. This reduction not only consolidates stock ownership but also modifies the authorized shares, decreasing them from 800 million to about 53.3 million. The planned adjustments also encompass the equity incentive plans, outstanding equity awards, and convertible notes, ensuring that all stockholders receive equivalent proportions in the aftermath of the stock adjustment.

Karyopharm’s stock is slated to commence trading on a split-adjusted basis on February 26, 2025, under the existing symbol